Embodiments of the present disclosure may relate to a system and method for evaluating physiological parameter data. In embodiments, a medical device may be capable of calculating an airway instability index from pulse oximetry measurements and generating a smoothed index representing airway instability.
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present disclosure, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with information to facilitate a better understanding of the various aspects of the present disclosure. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
Obstructive sleep apnea is a condition in which a patient's breathing is temporarily interrupted when sleeping. The condition is believed to be associated with increased fat deposits in the neck, which commonly occur as a patient ages. These increased fat deposits may lead to a narrowing of the airway. When muscle tone diminishes during sleep, the narrowed airway can collapse during inhalation, effectively stopping and/or severely limiting air movement. At this point, the choking patient typically attempts to inhale more deeply, which generally results in further collapsing the airway. With no air movement, the oxygen level in the patient's bloodstream falls, finally reaching a point where the patient is aroused out of sleep. Upon arousal, the muscle tone increases, the airway opens and air flow to the lungs is precipitously restored. The patient hyperventilates, which quickly restores the blood oxygen levels to normal levels. The period of arousal is brief, so the patient is often unaware that the event took place. The patient returns to sleeping and the cycle often repeats.
Over time, this repeating cycle of low oxygen levels in the bloodstream can damage the heart and lead to other serious medical complications. Obstructive sleep apnea is believed to be one of the most common disorders in the United States and an important cause of heart attack and stroke. However, unlike other common medical disorders, such as diabetes, no simple diagnostic test has been developed to determine if a patient has sleep apnea. Tests do exist that can be used to diagnose sleep apnea, but the tests typically involve an overnight sleep study, which can be costly and inconvenient. The need for a simple, low-cost diagnostic test has led medical personnel to try less expensive techniques, such as pulse oximetry, to diagnose the presence of obstructive sleep apnea.
Certain aspects of embodiments of this disclosure are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the disclosure might take and that these aspects are not intended to limit the scope of the disclosure. Indeed, the disclosure may encompass a variety of aspects that may not be set forth below.
Embodiments may include a method of evaluating physiological parameter data. The method may include monitoring a patient to produce a signal including a sequence of numerical values for a physiological parameter over a time period and calculating an index from the signal. The index may be compared to a reported index and if the index is greater than the reported index, the reported index may be set to the value of the index. A modulation of the signal may be calculated and compared to a previous value of the modulation to identify a trend in the modulation. If the trend corresponds to an undesirable condition, a first function may be used to increase the reported index. The reported index may be used to provide an indication of a physiological status.
Embodiments may include a medical device including a sensor, a microprocessor, a memory, and a display. The sensor may be configured to produce a signal including a sequence of numerical values for a physiological parameter over a time period and the microprocessor may be configured to process the signal. The memory may be configured for storing programs and the contents of the memory may include machine readable instructions configured to direct the microprocessor to obtain the signal from the sensor and calculate an index from the signal. The instructions may, if executed, direct the microprocessor to compare the index to a reported index and if the index is greater than the reported index, set the reported index to the value of the index. The instructions may also direct the microprocessor to calculate a modulation of the signal and compare the modulation to a previous value of the modulation to identify a trend in the modulation. If the trend corresponds to an undesirable condition, the machine readable instructions may direct the microprocessor to increase the reported index using a first function. Finally, the memory may include instructions to direct the microprocessor to provide an indication of a physiological status based on the reported index.
Embodiments may include a tangible, machine readable medium that may include code which, if executed, may cause a microprocessor to obtain a signal made up of a sequence of numerical values for a physiological parameter over a time period and calculate an index from the signal. The tangible, machine readable medium may additionally include code that compares the index to a reported index and if the index is greater than the reported index, set the reported index to the value of the index, and code to calculate a modulation of the signal and compare the modulation to a previous value of the modulation to identify a trend in the modulation. If the trend corresponds to an undesirable condition, the code may increase the reported index using a first function. Finally, the tangible machine-readable medium may include code to provide an indication of a physiological status based on the reported index.
Advantages of the disclosure may become apparent upon reading the following detailed description and upon reference to the drawings in which:
Embodiments will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
Medical devices may be used to obtain signals representing physiological parameters from patients. However, these signals, which may be sequences of numerical values over time, may have too much information or noise to be effectively used in the diagnosis or treatment of certain medical conditions. Accordingly, the signals may be processed to generate a secondary series of numerical values over time, termed an index, which may provide a more useful representation of the status of the medical condition. In some applications, the index itself may be too responsive to noise or other factors to be easily analyzed. Embodiments may include methods that may be useful for processing an index calculated from a signal to generate a reported index having a decreased response to noise and other clinically insignificant events.
Thus, methods may assist in identifying problematic physiological conditions, while reducing the incidence of nuisance alarms. For example, in an embodiment, a method may increase the effectiveness of the use of oxygen saturation levels obtained from pulse oximetry in the diagnosis and treatment of sleep apnea. However, one of ordinary skill in the art will recognize that the method described below is not limited to pulse oximetry and may be implemented on other systems to calculate indices reflective of other physiological conditions. Examples of such indices may include indices reflective of heart rate variability, brain activity, glucose levels, and other measurements.
In an embodiment, the microprocessor 16 may be connected to random access memory (RAM) 18 and/or read-only memory (ROM) 20. The RAM 18 may be used to store the signals from the sensor 12 and the results of calculations that the microprocessor 16 performs. The ROM 20 may contain code, e.g., machine readable instructions, to direct the microprocessor 16 in collecting and processing the signal. In an embodiment, the microprocessor 16 may be connected to an input device 22 which may be used for local entry of control and calculation parameters for the medical device 10. A display unit 24 may be connected to the microprocessor 16 to display the results the microprocessor 16 has generated from the signal representing the physiological parameter.
In an embodiment, the microprocessor 16 may also be connected to a network interface 26 for the transfer of data from the microprocessor 16 to devices connected to a local area network 28. In an embodiment, the transferred data may include signal data, indices representing the status of physiological conditions, alarm signals, other data, and/or any combination thereof. The transferred data may also consist of control signals from the devices on the local area network 28, for example, to instruct the medical device 10 to send signal data, or other information, to a device on the local area network 28.
In embodiments, the medical device 10 may be used to calculate a reported index with the data collected from the sensor 12, using the method discussed below. The reported index may be output to the display unit 24 or sent to a network device on the local area network 28. The processing may take place in real time, or may be run after the data collection is completed for later determination of an index representing a physiological parameter.
In embodiments, a network device located on the local area network 28 may be used to calculate a reported index with the data collected from the sensor 12, using the method discussed below. The network device may request that the signal be sent from the medical device 10 through the network interface 26. As for the embodiment discussed above, the network device may be used to either determine an index representing a physiological condition in real time or to process a previously collected signal.
In an embodiment, the value of the index representing a physiological condition may be used to trigger one or more alarms, alerting practitioners to clinically important conditions. These alarms may appear on devices on the local area network 28, for example, a patient monitoring screen in an ICU. Alternatively, the alarms may appear on the display unit 24 of the medical device 10. Further, it may be advantageous to activate alarms in both locations using the results from either a local calculation on the medical device 10 or from a remote calculation on a network device connected to the local area network 28.
Embodiments may include a method for the calculation of a smoothed, reported index indicating the status of a medical condition. The method may be used to calculate a reported index indicative of airway instability from blood oxygen saturation data (SpO2). An airway instability index may be used to sound alarms during apnea events or to automatically control treatment systems. The method may utilize information that may occur during each sleep apnea event, called a desaturation pattern or pattern, in which the blood oxygen level falls slowly as oxygen stores in the body are used up, and then sharply recovers as the patient is aroused and hyperventilates. The recurring apnea events may occur in groups of at least two successive patterns, called clusters. In an embodiment, the severity of the apnea may be determined from the number of patterns in each cluster, the time between each pattern, the slope of the drop in the blood oxygen level during a pattern and the slope of the recovery of the blood oxygen level as the patterns ends, and other indications, and/or combinations thereof, among others.
In embodiments, the method may use a number of indices, which may be calculated from the clusters and patterns, to indicate the presence or severity of airway instability, which may be directly related to obstructive sleep apnea, and/or other apneaic events. Embodiments of these indices may include a saturation to ventilation index, an oxygen repletion index, and/or an apnea recovery index, and/or combinations thereof, among others.
In an embodiment, an aggregate index may also be calculated based on the number of breaths, the relative magnitude of the breaths, the slope of the initial 50% of the descending limbs of the desaturations within the cluster and the duration of the clusters, and/or combinations thereof. Embodiments may include an index representing airway instability and may be calculated in a similar manner to those discussed in U.S. Pat. No. 6,760,608 (hereinafter the '608 patent), incorporated by reference as if fully set forth herein. Although the airway instability index may provide a numerical measure of the airway instability and, thus, the presence of apnea, it may have too high of a response to noise or other small changes to be desirable.
In accordance with some embodiments, the airway instability index may include a saturation pattern detection index (SPDi). The SPDi may be defined as a scoring metric associated with the identification of a saturation trend pattern generated in accordance with present embodiment and may correlate to ventilatory instability in a population of sleep lab patients. Specifically, the SPDi may be based on identified clusters of qualified reciprocations in pulse oximetry data. The reciprocations may be identified and qualified using methods and devices as set forth in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008, which is incorporated herein by reference in its entirety.
In order to calculate the SPDi, the patterns (i.e., clusters of qualified reciprocations) in SpO2 trend data must first be detected. Accordingly, present embodiments may include code stored on a tangible, computer-readable medium (e.g., a memory) and/or hardware (in the medical device 10 and/or a computer, for instance) capable of detecting the presence of certain patterns in a series of physiologic data. For example,
Specifically, in the illustrated embodiment, the electronic device 100 includes a reciprocation detection (RD) feature 102, a reciprocation qualification (RQ) feature 104, a cluster determination (CD) feature 106, a saturation pattern detection index (SPDi) calculation feature 108, and a user notification (UN) feature 110. Each of these components and the coordination of their functions will be summarized and discussed in further detail below. Additional description of these features may be found in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008, which is incorporated herein by reference in its entirety.
The RD feature 102 may be capable of performing an algorithm for detecting reciprocations in a data trend. Specifically, the algorithm of the RD feature 102 may perform a statistical method to find potential reciprocation peaks and nadirs in a trend of SpO2 data. A nadir may be defined as a minimum SpO2 value in a reciprocation. The peaks may include a rise peak (e.g., a maximum SpO2 value in a reciprocation that occurs after the nadir) and/or a fall peak (e.g., a maximum SpO2 value in a reciprocation that occurs before the nadir).
In one embodiment, a window size for calculations related to identifying peaks and nadirs may be set based on historical values (e.g., average duration of a set number of previous reciprocations). For example, in one embodiment, a window size may be set to the average duration of all qualified reciprocations in a certain time period (e.g., the last 6 minutes) divided by 2. In another embodiment, a dynamic window method may be utilized wherein the window size may be initially set to a certain amount of time (e.g., 12 seconds) and then increased as the length of qualified reciprocations increases. This may be done in anticipation of larger reciprocations because reciprocations that occur next to each other tend to be of similar shape and size. If the window remained at the initial time setting (e.g., 12 seconds), it could potentially be too short for larger reciprocations and may prematurely detect peaks and nadirs. The following equation or calculation is representative of a window size determination, wherein the output of the filter is inclusively limited to 12-36 seconds, and the equation is executed each time a new reciprocation is qualified:
If no qualified reciprocations in the last 6 minutes:
Window Size=12 (initial value)
else:
RecipDur=½*current qualified recip duration+½*previous RecipDur
Window Size=bound(RecipDur,12,36).
With regard to SpO2 signals that are essentially flat, the dynamic window method may fail to find the three points (i.e., a fall peak, a rise peak, and a nadir) utilized to identify a potential reciprocation. Therefore, the RD feature 102 may limit the amount of time that the dynamic window method can search for a potential reciprocation. For example, if no reciprocations are found in 240 seconds plus the current dynamic window size, the algorithm of the RD feature 102 may timeout and begin to look for potential reciprocations at the current SpO2 trend point and later. The net effect of this may be that the RD feature 102 detects potential reciprocations less than 240 seconds long.
Once potential peaks and nadirs are found using the RD feature 102, the RQ feature 104 may pass the potential reciprocations through one or more qualification stages to determine if a related event is caused by ventilatory instability. A first qualification stage may include checking reciprocation metrics against a set of limits (e.g., predetermined hard limits). A second qualification stage may include a linear qualification function. In accordance with present embodiments, a potential reciprocation may be required to pass through both stages in order to be qualified. Details regarding these qualification stages may be found in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008, which is incorporated herein by reference in its entirety.
As an example, in a first qualification stage, which may include a limit-based qualification, four metrics may be calculated for each potential reciprocation and compared to a set of limits. Any reciprocation with a metric that falls outside of these limits may be disqualified. The limits may be based on empirical data. For example, in some embodiments, the limits may be selected by calculating the metrics for potential reciprocations from sleep lab data where ventilatory instability is known to be present, and then comparing the results to metrics from motion and breathe-down studies. The limits may then be refined to filter out true positives.
A second qualification stage of the RQ feature 104 may utilize a object reciprocation qualification feature. Specifically, the second qualification stage may utilize a linear qualification function based on ease of implementation, efficiency, and ease of optimization. The equation may be determined by performing a least squares analysis. For example, such an analysis may be performed with MATLAB®. The inputs to the equation may include the set of metrics disclosed in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008. The output may be optimized to a maximum value for patterns where ventilatory instability is known to be present. The equation may be optimized to output smaller values (e.g., 0) for other data sets where potential false positive reciprocations are abundant.
The CD feature 106 may be capable of performing an algorithm that maintains an internal reciprocation counter that keeps track of a number of qualified reciprocations that are currently present. When the reciprocation counter is greater than or equal to a certain value, such as 5, the clustering state may be set to “active” and the algorithm may begin calculating and reporting the SPDi. When clustering is not active (e.g., reciprocation count<5) the algorithm may not calculate the SPDi. Once clustering is active, it may remain active until the time between two qualified reciprocations exceeds a certain time value, such as 120 seconds.
When the clustering state is active, the SPDi calculation feature 108 may calculate an unfiltered SPDi for each new qualified reciprocation. The following formula is an example of a formula that may be used by the SPDi calculation feature 108:
Unfiltered SPDi=a*Magnitude+b*PeakDelta+c*NadirDelta;
wherein a=1.4, b=2.0, c=0.2;
wherein Magnitude=average magnitude of all reciprocations in the last 6 minutes;
wherein PeakDelta=average of the three highest qualified reciprocation rise peaks in the last 6 minutes minus the average of the three lowest qualified reciprocation rise peaks in the last 6 minutes; and
wherein NadirDelta=average of the three highest qualified reciprocation nadirs in the last 6 minutes minus the average of the three lowest qualified reciprocation nadirs in the last 6 minutes.
The above formula may be utilized to quantify the severity of a ventilatory instability pattern. The constants and metrics used may be based on input from clinical team members. It should be noted that the PeakDelta parameter may be assigned the largest weighting constant since the most severe patterns generally have peak reciprocation values that do not recover to the same baseline.
The unfiltered SPDi may be updated whenever clustering is active and a new qualified reciprocation is detected. Non-zero SPDi values may be latched for a period of time (e.g., 6 minutes). The unfiltered SPDi may then be low pass filtered to produce the final output SPDi value. The following infinite impulse response (IIR) filter with a response time of approximately 40 seconds is an example of what may be used:
SPDi=Unfiltered SPDi/a+Previous Filtered SPDi*(a−1)/a;
wherein a=40.
The UN feature 110 may be capable of determining if a user notification function should be employed to notify a user (e.g., via a graphical or audible indicator) of the presence of a detected patterns such as ventilatory instability. The determination of the UN feature 110 may be based on a user configurable tolerance setting and the current value of the SPDi. For example, the user may have four choices for the sensitivity or tolerance setting: Off, Low, Medium, and High. When the sensitivity or tolerance setting is set to Off, an alarm based on detection of a saturation pattern may never be reported to the user. The other three tolerance settings (i.e., Low, Medium, and High) may each map to an SPDi threshold value. For example, Low may map to an SPDi threshold of 6, Medium may map to an SPDi threshold of 15, and High may map to an SPDi threshold of 24. The thresholds may be based on input from users. When the SPDi is at or above the threshold for a given tolerance setting, the user may be notified that ventilatory instability is present.
In an embodiment, if a qualified pattern is detected, the starting time of the qualified pattern may be reported and a new airway instability index may be calculated, as shown in block 236. The airway instability index may be calculated, for example, by using the method set forth above, the method disclosed in the '608 patent, or the method disclosed in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008. One of ordinary skill in the art will appreciate that other methods may be used for calculation of an effective airway instability index.
In an embodiment, as shown in block 238, the new value for the airway instability index may be compared to the last value of the airway instability index, and if it is less than or equal to that value, the method 230 may proceed with the acts starting at block 240, as discussed below. The new value for the airway instability index may then be compared to the current value of the reported index, as shown in block 242, and if it is less then or equal to the current value of the reported index, the method 230 may proceed with the acts starting at block 240.
In an embodiment, if the new value for the airway instability index is greater than the current value of the reported index, the reported index may be set to the new value of the airway instability index, as shown in block 244. A decay coefficient may be then calculated for use in the remaining acts, as shown in block 246. In an embodiment, the decay coefficient may be calculated by the formula of the general form shown in equation 1:
R=T2/(Airway Instability Index), (equation 1)
where T is the desired decay period. In an embodiment, T is 180 seconds. Those skilled in the art will recognize that other values may be used for T, and in fact, T may be tuned to give optimum values needed for the particular application and index selected.
In an embodiment, if no new pattern is detected, and/or upon completion of the acts discussed above, in block 240, a value may be calculated for the percent modulation of the SpO2 trend over the duration of the current qualified pattern. In an embodiment, a fixed or variable length sliding window could also be for the percent modulation and mean calculations. In an embodiment, this calculation may be performed using the formula of the general form shown in equation 2:
Percent Modulation=(SpO2max−SpO2min)/SpO2mean. (equation 2)
As shown in block 248, the calculated value for the percent modulation may be compared to the previous value of the percent modulation. If the percent modulation has decreased or is unchanged from the last value, the reported index may be decreased, as shown in block 250. In an embodiment, this decrease in the reported index may be performed by using the parabolic decay function of the general form shown in equation 3:
New Reported Index=Previous Preported Index−(2N/R), (equation 3)
where N is the duration of the current qualified pattern in seconds, calculated from the starting time recorded in block 236, and R is the decay coefficient calculated in equation 1. If the value calculated for the reported index is less than zero, the reported index may be set to zero. One of ordinary skill in the art will recognize that other functions may be selected for decreasing the value of the new unfiltered index. Such functions may include exponential decay functions, quadratic functions, and/or other functions appropriate for the application and index selected. The choice of the function may depend on, for example, the noise of the unfiltered index, the sensitivity desired, and/or the desired response to sudden changes in the index. In an embodiment, an exponential decay function may be desired if a faster response to changes is desirable.
In an embodiment, if the value for percent modulation has increased, the instability index may be increased, as shown in block 252. In an embodiment, this calculation may be performed using a parabolic growth function of the general form shown in equation 4:
New Reported Index=Previous Reported Index+(2N/R), (equation 4)
where N is the duration of the current qualified pattern in seconds, calculated from the starting time recorded in block 236, and R is the decay coefficient calculated in block 246. If the value calculated for the reported index is greater then a maximum value for the airway instability index selected, then the reported index may be set to the maximum value. One skilled in the art will recognize that other functions may be selected for increasing the value of the reported index. Such functions may include exponential growth functions, quadratic functions, or other functions appropriate for the application and index selected. The selection of an appropriate function will depend on the responsiveness desired, as the function will control how fast the reported index increases or decreases.
In an embodiment, the reported index may be subjected to a filtering step prior to reporting the value of the index, as shown in block 254. In an embodiment, this filtering step may be performed by an infinite impulse response (IIR) filter, of the general form shown in equation 5:
Reported Index=New Reported Index/W+Previous Reported Index*((W−1)/W), (equation 5)
where W is the IIR filter weight. In an embodiment, a weight of four is used. One skilled in the art will recognize that other weights, or even other functions, may be selected for filtering the value of the new unfiltered index. Alternate weights may be selected to optimize performance of the filter for the index selected. Examples of other filtering functions that may be used include functions such as mean filters, median filters, Gaussian smoothing functions, Savitzky-Golay filters, and/or other functions appropriate for the application and index selected. The choice of the filtering function depends on factors such as the sensitivity desired and the amount of tolerable fluctuation, or noise, in the index, among others.
The SpO2 signal 260 may be used to calculate an airway instability index 262, which may be useful in determining if a patient is having an episode of obstructive sleep apnea and/or other event. The airway instability index 262 may also be used by the method 230 discussed with respect to
The line 268, drawn across the chart at the 85% level for SpO2, may indicate a level that may generally be considered important by practitioners. This level may be used as a setpoint in embodiments.
In contrast, the reported index 264, generated by the method 230 discussed with respect to
A practitioner may be more likely to be concerned with significant shifts upward in the airway instability index 262, than with the downward shifts discussed above. As shown in blocks 242 and 244 of the flowchart in
In an embodiment, the stability of the method 230 to fast changes in the airway instability index 262, e.g., noise, is also demonstrated in
In an embodiment, the decreased response to noise provided by the method 230 is further illustrated by the chart in
While the present disclosure described above may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the present disclosure is not intended to be limited to calculating an airway instability index. Indeed, the present disclosure may not only be applied to airway instability indices, but may also be utilized for the reporting of other physiological parameters needing a high response to significant events with low noise. The present disclosure is intended to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the following appended claims.
This application claims priority to U.S. Provisional Application No 61/066,181, filed Feb. 19, 2008, and is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3638640 | Shaw | Feb 1972 | A |
4106503 | Rosenthal et al. | Aug 1978 | A |
4365636 | Barker | Dec 1982 | A |
4523279 | Sperinde | Jun 1985 | A |
4630614 | Atlas | Dec 1986 | A |
4651746 | Wall | Mar 1987 | A |
4714341 | Hamaguri et al. | Dec 1987 | A |
4738266 | Thatcher | Apr 1988 | A |
4757824 | Chaumet | Jul 1988 | A |
4765340 | Sakai et al. | Aug 1988 | A |
4802485 | Bowers et al. | Feb 1989 | A |
4805623 | Jöbsis | Feb 1989 | A |
4807631 | Hersh et al. | Feb 1989 | A |
4869253 | Craig | Sep 1989 | A |
4911167 | Corenman et al. | Mar 1990 | A |
4913150 | Cheung et al. | Apr 1990 | A |
4936679 | Mersch | Jun 1990 | A |
4938218 | Goodman et al. | Jul 1990 | A |
4971062 | Hasebe et al. | Nov 1990 | A |
4972331 | Chance | Nov 1990 | A |
4974591 | Awazu et al. | Dec 1990 | A |
5028787 | Rosenthal et al. | Jul 1991 | A |
5065749 | Hasebe et al. | Nov 1991 | A |
5084327 | Stengel | Jan 1992 | A |
5111817 | Clark et al. | May 1992 | A |
5119815 | Chance | Jun 1992 | A |
5122974 | Chance | Jun 1992 | A |
5123420 | Paret | Jun 1992 | A |
5134995 | Gruenke et al. | Aug 1992 | A |
5167230 | Chance | Dec 1992 | A |
5190038 | Polson et al. | Mar 1993 | A |
5199424 | Sullivan | Apr 1993 | A |
5206807 | Hatke | Apr 1993 | A |
5218962 | Mannheimer et al. | Jun 1993 | A |
5233983 | Markowitz | Aug 1993 | A |
5246003 | DeLonzor | Sep 1993 | A |
5247931 | Norwood | Sep 1993 | A |
5263244 | Centa et al. | Nov 1993 | A |
5275159 | Griebel | Jan 1994 | A |
5279295 | Martens et al. | Jan 1994 | A |
5297548 | Pologe | Mar 1994 | A |
5303699 | Bonassa et al. | Apr 1994 | A |
5318597 | Hauck et al. | Jun 1994 | A |
5329931 | Clauson et al. | Jul 1994 | A |
5335654 | Rapoport | Aug 1994 | A |
5353788 | Miles | Oct 1994 | A |
5355880 | Thomas et al. | Oct 1994 | A |
5368026 | Swedlow et al. | Nov 1994 | A |
5372136 | Steuer et al. | Dec 1994 | A |
5385143 | Aoyagi | Jan 1995 | A |
5385144 | Yamanishi et al. | Jan 1995 | A |
5390670 | Centa et al. | Feb 1995 | A |
5398682 | Lynn | Mar 1995 | A |
5413099 | Schmidt et al. | May 1995 | A |
5469845 | DeLonzor et al. | Nov 1995 | A |
5482036 | Diab et al. | Jan 1996 | A |
5483646 | Uchikoga | Jan 1996 | A |
5483969 | Testerman | Jan 1996 | A |
5485851 | Erickson | Jan 1996 | A |
5490502 | Rapoport et al. | Feb 1996 | A |
5535739 | Rapoport et al. | Jul 1996 | A |
5540733 | Testerman et al. | Jul 1996 | A |
5549106 | Gruenke et al. | Aug 1996 | A |
5551419 | Froehlich et al. | Sep 1996 | A |
5553614 | Chance | Sep 1996 | A |
5564417 | Chance | Oct 1996 | A |
5575285 | Takanashi et al. | Nov 1996 | A |
5605151 | Lynn | Feb 1997 | A |
5611337 | Bukta | Mar 1997 | A |
5630413 | Thomas et al. | May 1997 | A |
5632270 | O'Mahony et al. | May 1997 | A |
5645053 | Remmers et al. | Jul 1997 | A |
5645054 | Cotner et al. | Jul 1997 | A |
5645059 | Fein et al. | Jul 1997 | A |
5645060 | Yorkey | Jul 1997 | A |
5680857 | Pelikan et al. | Oct 1997 | A |
5682878 | Ogden | Nov 1997 | A |
5692503 | Keunstner | Dec 1997 | A |
5704345 | Berthon/Jones | Jan 1998 | A |
5730124 | Yamauchi | Mar 1998 | A |
5730144 | Katz et al. | Mar 1998 | A |
5740795 | Brydon | Apr 1998 | A |
5743250 | Gonda et al. | Apr 1998 | A |
5749900 | Schroeppel et al. | May 1998 | A |
5751911 | Goldman | May 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5765563 | Vander Schaaf | Jun 1998 | A |
5769084 | Katz et al. | Jun 1998 | A |
5779631 | Chance | Jul 1998 | A |
5782240 | Raviv et al. | Jul 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5786592 | Hök | Jul 1998 | A |
5794614 | Gruenke et al. | Aug 1998 | A |
5794615 | Estes | Aug 1998 | A |
5803065 | Zdrojkowski et al. | Sep 1998 | A |
5803066 | Rapoport et al. | Sep 1998 | A |
5823187 | Estes et al. | Oct 1998 | A |
5827179 | Lichter et al. | Oct 1998 | A |
5830135 | Bosque et al. | Nov 1998 | A |
5830136 | DeLonzor et al. | Nov 1998 | A |
5830139 | Abreu | Nov 1998 | A |
5831598 | Kauffert et al. | Nov 1998 | A |
5842981 | Larsen et al. | Dec 1998 | A |
5845636 | Gruenke et al. | Dec 1998 | A |
5853364 | Baker et al. | Dec 1998 | A |
5865173 | Froehlich | Feb 1999 | A |
5865736 | Baker, Jr. et al. | Feb 1999 | A |
5871442 | Madarasz et al. | Feb 1999 | A |
5873821 | Chance et al. | Feb 1999 | A |
5891022 | Pologe | Apr 1999 | A |
5891023 | Lynn | Apr 1999 | A |
5902250 | Verrier et al. | May 1999 | A |
5920263 | Huttenhoff et al. | Jul 1999 | A |
5957885 | Bollish | Sep 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5995856 | Mannheimer et al. | Nov 1999 | A |
5995859 | Takahashi | Nov 1999 | A |
6006379 | Hensley | Dec 1999 | A |
6011986 | Diab et al. | Jan 2000 | A |
6015388 | Sackner et al. | Jan 2000 | A |
6064898 | Aldrich | May 2000 | A |
6081742 | Amano et al. | Jun 2000 | A |
6083156 | Lisiecki | Jul 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6105575 | Estes et al. | Aug 2000 | A |
6120441 | Griebel | Sep 2000 | A |
6120460 | Abreu | Sep 2000 | A |
6134460 | Chance | Oct 2000 | A |
6138675 | Berthon/Jones | Oct 2000 | A |
6144877 | DePetrillo | Nov 2000 | A |
6148814 | Clemmer et al. | Nov 2000 | A |
6150951 | Olejniczak | Nov 2000 | A |
6154667 | Miura et al. | Nov 2000 | A |
6163715 | Larsen et al. | Dec 2000 | A |
6181958 | Steuer et al. | Jan 2001 | B1 |
6181959 | Schöllermann et al. | Jan 2001 | B1 |
6190324 | Kieval et al. | Feb 2001 | B1 |
6215403 | Chan et al. | Apr 2001 | B1 |
6216032 | Griffin et al. | Apr 2001 | B1 |
6223064 | Lynn et al. | Apr 2001 | B1 |
6230035 | Aoyagi et al. | May 2001 | B1 |
6266546 | Steuer et al. | Jul 2001 | B1 |
6285895 | Ristolainen et al. | Sep 2001 | B1 |
6286508 | Remmers et al. | Sep 2001 | B1 |
6299581 | Rapoport et al. | Oct 2001 | B1 |
6305374 | Zdrojkowski et al. | Oct 2001 | B1 |
6312393 | Abreu | Nov 2001 | B1 |
6322515 | Goor et al. | Nov 2001 | B1 |
6342039 | Lynn et al. | Jan 2002 | B1 |
6345619 | Finn | Feb 2002 | B1 |
6353750 | Kimura et al. | Mar 2002 | B1 |
6360114 | Diab et al. | Mar 2002 | B1 |
6367474 | Berthon/Jones et al. | Apr 2002 | B1 |
6371113 | Tobia et al. | Apr 2002 | B1 |
6375623 | Gavriely | Apr 2002 | B1 |
6397091 | Diab et al. | May 2002 | B2 |
6397092 | Norris et al. | May 2002 | B1 |
6401713 | Hill et al. | Jun 2002 | B1 |
6415236 | Kobayashi et al. | Jul 2002 | B2 |
6419671 | Lemberg | Jul 2002 | B1 |
6425861 | Haberland et al. | Jul 2002 | B1 |
6438399 | Kurth | Aug 2002 | B1 |
6449501 | Reuss | Sep 2002 | B1 |
6461305 | Schnall | Oct 2002 | B1 |
6463326 | Hartley et al. | Oct 2002 | B1 |
6466809 | Riley | Oct 2002 | B1 |
6487439 | Skladnev et al. | Nov 2002 | B1 |
6488634 | Rapoport et al. | Dec 2002 | B1 |
6501974 | Huiku | Dec 2002 | B2 |
6501975 | Diab et al. | Dec 2002 | B2 |
6502572 | Berthon/Jones et al. | Jan 2003 | B1 |
6519486 | Edgar, Jr. et al. | Feb 2003 | B1 |
6526301 | Larsen et al. | Feb 2003 | B2 |
6529752 | Krausman et al. | Mar 2003 | B2 |
6532960 | Yurko | Mar 2003 | B1 |
6539940 | Zdrojkowski et al. | Apr 2003 | B2 |
6542764 | Al/Ali et al. | Apr 2003 | B1 |
6544193 | Abreu | Apr 2003 | B2 |
6546267 | Sugiura et al. | Apr 2003 | B1 |
6549795 | Chance | Apr 2003 | B1 |
6572557 | Tchou et al. | Jun 2003 | B2 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6591122 | Schmitt | Jul 2003 | B2 |
6594513 | Jobsis et al. | Jul 2003 | B1 |
6606509 | Schmitt | Aug 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6609016 | Lynn | Aug 2003 | B1 |
6609517 | Estes et al. | Aug 2003 | B1 |
6615064 | Aldrich | Sep 2003 | B1 |
6618042 | Powell | Sep 2003 | B1 |
6622095 | Kobayashi et al. | Sep 2003 | B2 |
6622726 | Du | Sep 2003 | B1 |
6637434 | Noble | Oct 2003 | B2 |
6640806 | Yurko | Nov 2003 | B2 |
6641542 | Cho et al. | Nov 2003 | B2 |
6654621 | Palatnik et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kianl et al. | Dec 2003 | B2 |
6658277 | Wasserman | Dec 2003 | B2 |
6661161 | Lanzo et al. | Dec 2003 | B1 |
6662030 | Khalil et al. | Dec 2003 | B2 |
6668183 | Hicks et al. | Dec 2003 | B2 |
6671526 | Aoyagi et al. | Dec 2003 | B1 |
6671528 | Steuer et al. | Dec 2003 | B2 |
6675797 | Berthon/Jones | Jan 2004 | B1 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6690958 | Walker et al. | Feb 2004 | B1 |
6691705 | Dittman et al. | Feb 2004 | B2 |
6697658 | Al-Ali | Feb 2004 | B2 |
6708048 | Chance | Mar 2004 | B1 |
6711424 | Fine et al. | Mar 2004 | B1 |
6711425 | Reuss | Mar 2004 | B1 |
6714245 | Ono | Mar 2004 | B1 |
6719705 | Mills | Apr 2004 | B2 |
6731274 | Powell | May 2004 | B2 |
6745764 | Hickle | Jun 2004 | B2 |
6748252 | Lynn | Jun 2004 | B2 |
6760608 | Lynn | Jul 2004 | B2 |
6761167 | Nadjafizadeh et al. | Jul 2004 | B1 |
6785568 | Chance | Aug 2004 | B2 |
6793654 | Lemberg | Sep 2004 | B2 |
6801797 | Mannheimer et al. | Oct 2004 | B2 |
6801798 | Geddes et al. | Oct 2004 | B2 |
6801799 | Mendelson | Oct 2004 | B2 |
6804656 | Rosenfeld et al. | Oct 2004 | B1 |
6807965 | Hickle | Oct 2004 | B1 |
6814074 | Nadjafizadeh et al. | Nov 2004 | B1 |
6817361 | Berthon/Jones et al. | Nov 2004 | B2 |
6822564 | Al/Ali | Nov 2004 | B2 |
6829496 | Nagai et al. | Dec 2004 | B2 |
6832200 | Greeven et al. | Dec 2004 | B2 |
6839581 | El-Solh et al. | Jan 2005 | B1 |
6850053 | Daalmans et al. | Feb 2005 | B2 |
6863652 | Huang et al. | Mar 2005 | B2 |
6873865 | Steuer et al. | Mar 2005 | B2 |
6889153 | Dietiker | May 2005 | B2 |
6896660 | Jelliffe et al. | May 2005 | B2 |
6898451 | Wuori | May 2005 | B2 |
6932084 | Estes et al. | Aug 2005 | B2 |
6939307 | Dunlop | Sep 2005 | B1 |
6947780 | Scharf | Sep 2005 | B2 |
6948497 | Zdrojkowski et al. | Sep 2005 | B2 |
6949081 | Chance | Sep 2005 | B1 |
6961598 | Diab | Nov 2005 | B2 |
6983178 | Fine et al. | Jan 2006 | B2 |
6988498 | Berthon-Jones | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
7006676 | Zeylikovich et al. | Feb 2006 | B1 |
7024235 | Melker et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7031857 | Tarassenko et al. | Apr 2006 | B2 |
7035697 | Brown | Apr 2006 | B1 |
7047056 | Hannula et al. | May 2006 | B2 |
7081095 | Lynn et al. | Jul 2006 | B2 |
7090648 | Sackner et al. | Aug 2006 | B2 |
7123950 | Mannheimer | Oct 2006 | B2 |
7127278 | Melker et al. | Oct 2006 | B2 |
7153263 | Carter et al. | Dec 2006 | B2 |
7162306 | Caby et al. | Jan 2007 | B2 |
7209775 | Bae et al. | Apr 2007 | B2 |
7225013 | Geva et al. | May 2007 | B2 |
7236811 | Schmitt | Jun 2007 | B2 |
7246620 | Conroy, Jr. | Jul 2007 | B2 |
7247154 | Hickle | Jul 2007 | B2 |
7263395 | Chan et al. | Aug 2007 | B2 |
7272426 | Schmid | Sep 2007 | B2 |
7297119 | Westbrook et al. | Nov 2007 | B2 |
7309314 | Grant et al. | Dec 2007 | B2 |
7338447 | Phillips | Mar 2008 | B2 |
7349727 | Obata et al. | Mar 2008 | B2 |
7366569 | Belalcazar | Apr 2008 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7383105 | Conroy, Jr. | Jun 2008 | B2 |
7398115 | Lynn | Jul 2008 | B2 |
7407486 | Huiku et al. | Aug 2008 | B2 |
7438687 | Lewicke | Oct 2008 | B2 |
7460909 | Koh et al. | Dec 2008 | B1 |
7539533 | Tran | May 2009 | B2 |
20010005773 | Larsen et al. | Jun 2001 | A1 |
20010020122 | Steuer et al. | Sep 2001 | A1 |
20010039376 | Steuer et al. | Nov 2001 | A1 |
20010044700 | Kobayashi et al. | Nov 2001 | A1 |
20020026106 | Khalil et al. | Feb 2002 | A1 |
20020035318 | Mannheimer et al. | Mar 2002 | A1 |
20020038079 | Steuer et al. | Mar 2002 | A1 |
20020042558 | Mendelson | Apr 2002 | A1 |
20020049389 | Abreu | Apr 2002 | A1 |
20020062071 | Diab et al. | May 2002 | A1 |
20020111748 | Kobayashi et al. | Aug 2002 | A1 |
20020117173 | Lynn et al. | Aug 2002 | A1 |
20020133068 | Huiku | Sep 2002 | A1 |
20020156354 | Larson | Oct 2002 | A1 |
20020161287 | Schmitt | Oct 2002 | A1 |
20020161290 | Chance | Oct 2002 | A1 |
20020165439 | Schmitt | Nov 2002 | A1 |
20020198443 | Ting | Dec 2002 | A1 |
20030023140 | Chance | Jan 2003 | A1 |
20030055324 | Wasserman | Mar 2003 | A1 |
20030060693 | Monfre et al. | Mar 2003 | A1 |
20030139687 | Abreu | Jul 2003 | A1 |
20030144584 | Mendelson | Jul 2003 | A1 |
20030158466 | Lynn | Aug 2003 | A1 |
20030220548 | Schmitt | Nov 2003 | A1 |
20030220576 | Diab | Nov 2003 | A1 |
20040010188 | Wasserman | Jan 2004 | A1 |
20040015091 | Greenwald et al. | Jan 2004 | A1 |
20040054270 | Pewzner et al. | Mar 2004 | A1 |
20040087846 | Wasserman | May 2004 | A1 |
20040107065 | Al-Ali | Jun 2004 | A1 |
20040111014 | Hickle | Jun 2004 | A1 |
20040127779 | Steuer et al. | Jul 2004 | A1 |
20040171920 | Mannheimer et al. | Sep 2004 | A1 |
20040176670 | Takamura et al. | Sep 2004 | A1 |
20040176671 | Fine et al. | Sep 2004 | A1 |
20040230106 | Schmitt et al. | Nov 2004 | A1 |
20050016536 | Rapoport et al. | Jan 2005 | A1 |
20050043763 | Marcovecchio et al. | Feb 2005 | A1 |
20050080323 | Kato | Apr 2005 | A1 |
20050081854 | Nadjafizadeh et al. | Apr 2005 | A1 |
20050101850 | Parker | May 2005 | A1 |
20050113651 | Wood et al. | May 2005 | A1 |
20050113656 | Chance | May 2005 | A1 |
20050113709 | Millet | May 2005 | A1 |
20050119586 | Coyle et al. | Jun 2005 | A1 |
20050143665 | Huiku et al. | Jun 2005 | A1 |
20050168722 | Forstner et al. | Aug 2005 | A1 |
20050177034 | Beaumont | Aug 2005 | A1 |
20050187480 | Kario et al. | Aug 2005 | A1 |
20050192488 | Bryenton et al. | Sep 2005 | A1 |
20050203357 | Debreczeny et al. | Sep 2005 | A1 |
20050228248 | Dietiker | Oct 2005 | A1 |
20050267346 | Faber et al. | Dec 2005 | A1 |
20050283059 | Iyer et al. | Dec 2005 | A1 |
20060009688 | Lamego et al. | Jan 2006 | A1 |
20060009809 | Marcovecchio et al. | Jan 2006 | A1 |
20060015021 | Cheng | Jan 2006 | A1 |
20060020181 | Schmitt | Jan 2006 | A1 |
20060030763 | Mannheimer et al. | Feb 2006 | A1 |
20060052680 | Diab | Mar 2006 | A1 |
20060058683 | Chance | Mar 2006 | A1 |
20060064024 | Schnall | Mar 2006 | A1 |
20060137577 | Chang et al. | Jun 2006 | A1 |
20060155207 | Lynn et al. | Jul 2006 | A1 |
20060161071 | Lynn et al. | Jul 2006 | A1 |
20060167362 | Neumann et al. | Jul 2006 | A1 |
20060173257 | Nagai et al. | Aug 2006 | A1 |
20060189880 | Lynn et al. | Aug 2006 | A1 |
20060195028 | Hannula et al. | Aug 2006 | A1 |
20060195041 | Lynn et al. | Aug 2006 | A1 |
20060217615 | Huiku et al. | Sep 2006 | A1 |
20060224058 | Mannheimer | Oct 2006 | A1 |
20060225737 | Iobbi | Oct 2006 | A1 |
20060235324 | Lynn | Oct 2006 | A1 |
20060247501 | Ali | Nov 2006 | A1 |
20060258921 | Addison et al. | Nov 2006 | A1 |
20060276695 | Lynn et al. | Dec 2006 | A9 |
20070027375 | Melker et al. | Feb 2007 | A1 |
20070066910 | Inukai et al. | Mar 2007 | A1 |
20070093721 | Lynn et al. | Apr 2007 | A1 |
20070119453 | Lu et al. | May 2007 | A1 |
20070123785 | Lu et al. | May 2007 | A1 |
20070149860 | Lynn et al. | Jun 2007 | A1 |
20070203406 | Anderson et al. | Aug 2007 | A1 |
20070208269 | Mumford et al. | Sep 2007 | A1 |
20070213619 | Linder | Sep 2007 | A1 |
20070213620 | Reisfeld | Sep 2007 | A1 |
20070213621 | Reisfeld et al. | Sep 2007 | A1 |
20070213622 | Reisfeld | Sep 2007 | A1 |
20070213624 | Reisfeld et al. | Sep 2007 | A1 |
20070238937 | Chang et al. | Oct 2007 | A1 |
20070240723 | Hong et al. | Oct 2007 | A1 |
20070276262 | Banet et al. | Nov 2007 | A1 |
20080009689 | Benaron et al. | Jan 2008 | A1 |
20080064965 | Jay et al. | Mar 2008 | A1 |
20080071155 | Kiani | Mar 2008 | A1 |
20080082018 | Sackner et al. | Apr 2008 | A1 |
20080091088 | Kiani | Apr 2008 | A1 |
20080139908 | Kurth | Jun 2008 | A1 |
20080177163 | Wang et al. | Jul 2008 | A1 |
20080177358 | Gammons | Jul 2008 | A1 |
20080188729 | Sato et al. | Aug 2008 | A1 |
20080200775 | Lynn | Aug 2008 | A1 |
20080221464 | Al-Ali | Sep 2008 | A1 |
20080262362 | Kolluri et al. | Oct 2008 | A1 |
20080275317 | Cho et al. | Nov 2008 | A1 |
20080287756 | Lynn | Nov 2008 | A1 |
20080312533 | Balberg et al. | Dec 2008 | A1 |
20080314385 | Brunner et al. | Dec 2008 | A1 |
Number | Date | Country |
---|---|---|
9 200 422.9 | Jul 1992 | DE |
0615723 | Mar 1993 | EP |
0459284 | Jan 1995 | EP |
0651971 | Oct 1995 | EP |
0709107 | May 1996 | EP |
0714670 | Jun 1996 | EP |
0722747 | Jul 1996 | EP |
0788805 | May 1998 | EP |
0968734 | Jan 2000 | EP |
1004325 | Jun 2000 | EP |
0700690 | Feb 2002 | EP |
0759791 | Aug 2002 | EP |
0934723 | Sep 2004 | EP |
1172123 | Oct 2004 | EP |
0875258 | Nov 2004 | EP |
1488743 | Dec 2004 | EP |
1790283 | May 2007 | EP |
63275325 | Nov 1988 | JP |
2005034472 | Feb 2005 | JP |
WO 8801149 | Feb 1988 | WO |
WO 9009146 | Aug 1990 | WO |
WO 9014121 | Nov 1990 | WO |
WO9111137 | Aug 1991 | WO |
WO 9211054 | Jul 1992 | WO |
WO 9222244 | Dec 1992 | WO |
WO9313706 | Jul 1993 | WO |
WO9316629 | Sep 1993 | WO |
WO 9406499 | Mar 1994 | WO |
WO 9423780 | Oct 1994 | WO |
WO 9532016 | Nov 1995 | WO |
WO9639927 | Dec 1996 | WO |
WO 9714462 | Apr 1997 | WO |
WO 9728838 | Aug 1997 | WO |
WO9851212 | Nov 1998 | WO |
WO 9924099 | May 1999 | WO |
WO 9945989 | Sep 1999 | WO |
WO0021438 | Apr 2000 | WO |
WO 0067827 | Nov 2000 | WO |
WO0117421 | Mar 2001 | WO |
WO0140776 | Jun 2001 | WO |
WO0176461 | Oct 2001 | WO |
WO0176471 | Oct 2001 | WO |
WO03039326 | May 2003 | WO |
WO03084396 | Oct 2003 | WO |
WO 2004047621 | Jun 2004 | WO |
WO2004105601 | Dec 2004 | WO |
WO 2005065757 | Jul 2005 | WO |
WO2006092624 | Sep 2006 | WO |
WO2007051066 | May 2007 | WO |
WO2008097411 | Aug 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20090210163 A1 | Aug 2009 | US |
Number | Date | Country | |
---|---|---|---|
61066181 | Feb 2008 | US |